Ikaros Cancer Vaccines aims to help enhance and disseminate educational knowledge on cancer vaccines and immunotherapy. If you have any questions or concerns about our Resources or Dr. Ioannides’ CV, please feel free to contact us with the email below today. 

Emai:  info@ikaroscancervaccines.com

*Constantin G. Ioannides, MD Anderson Cancer Center , 1985-2010*,

*Principal Creator, Pro-bono Creators-Advocate*

Federally Funded Principal Investigator-Contractor,(USP ’942, 261, ‘759)

Discoverer of  (E39) Phase II +(E75),Phase III Trial

Creator Enhanced E75, (USP’618). Co-Inventor,helper panel,include AE37,
(USP’402P)

Research citations > 3750, Since 2009 > 1250

Net Research Royalties for MDACC only: 2006-2015 > $ 1,000,000.00

*Texas Taxpayer Number: 32042720758

*Texas File Number: 0801323287

*2014. GALE report to investors: * 2 cancer immunotherapies led by *NeuVax*.
Both of these were developed at the MDACC and part of the DoD funding of
breast cancer. *NeuVax* is a synthetic peptide….The researcher at the MDACC
looked at the entire, this is a 1,255 immuno sequence for the most
immunodominant which is interesting that HER2 is …well conserved..

*This is a huge shift in thinking* because is.., how cancer presents
because it's evaded or escape to immune system.Our 2nd program, we've
brought in pre-clinically from MDACC, we finished the Phase 1.., we will be
presenting our Phase 1 study in about 26 patients at ASCO. We started our
Phase 2 study in Ovarian cancer. This is Folate Binding Protein, Receptor-a.